Lure and Nancy - November 13, 2017: Vetoquinol, a leading player in the animal health sector, and Plant Advanced Technologies PAT, a plant biotechnology company, announce Vetoquinol’s acquisition of an equity stake in Plant Advanced Technologies PAT. The transaction was carried out via a €500,000 reserved capital increase at a price of €25 per share resulting in the veterinary group holding an equity stake of just over 2% in PAT.
For the third quarter of 2017, the Vetoquinol Group posted sales of €88.3 million, up 5.2% from Q3 2016 at constant exchange rates. Sales of Essential products, driver of the Group’s strategy, came to €41.9 million, up 16.7% like-for-like. All three territories posted strong growth at constant exchange rates, particularly Asia Pacific (10.5%), while Europe and the Americas both recorded 4.1% growth.
At its meeting on July 26, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the financial statements for the first half of 2017.
Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2017
The registration document of Vetoquinol relative to fiscal year 2016, including the annual financial report relative to fiscal year 2016, was filed with the Autorité des marchés financiers ("the AMF") on April 26, 2017.
Consolidated sales for Q1 2017 amounted to €86.1 million, up 0.4% as reported from the same period last year. Sales were boosted by a 1.8% positive currency impact mainly related to non-European currencies. Q1 sales fell 1.4% like-for-like.
At its meeting on March 22, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2016 financial statements.
The Vetoquinol Group posted sales of €350.3 million for 2016, representing like-for-like growth of 4.3%. After a negative currency impact of 2.0% mainly linked to the British pound, Canadian dollar and Indian rupee, reported growth amounted to 2.3%.
Vetoquinol posted sales of €257.5 million for the first nine months of 2016, up 2.3% compared to the same period last year. Organic growth for the period came to 4.8%, curbed by a 2.5% negative currency impact.
The veterinary pharmaceutical company Vetoquinol launches its employer brand. For 83 years, Vetoquinol has been building its future, drawing on relationships of trust with its partners, the development of every employee, and its long-held belief of continuous improvement. Following on from its corporate brand, the company is now positioning itself as a high-quality employer.
Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2016
Sales growth across all territories : reference products up 5.0
The Registration document of Vetoquinol relative to fiscal year 2015, including the Annual financial report relative to fiscal year 2014, was filed with the Autorité des marchés financiers (“the AMF”) on April 26, 2016.
Vetoquinol posted Q1 2016 sales of €85.8 million, representing organic growth of 7.7%. Changes in exchange rates resulted in a negative currency impact of 2.1%; reported sales for the first three months of 2016 grew by 5.6%.
At its meeting on March 18, 2016, the Vetoquinol S.A. Board of Directors reviewed the Group’s results and approved the 2015 financial statements.
Vetoquinol has been listed on the Euronext Paris stock market since November 16th.
Composition of the bodies of Corporate Management and Governance
Financial information and key figures: annual, half-year and by sector key figures